Neurofibroma

Neoplastic MONDO:0016755 Pathograph 15 Show in embeddings browser benign peripheral nerve sheath tumor

Neurofibroma is a benign peripheral nerve sheath tumor of the Schwann-cell lineage. The neoplastic Schwann cells arise after biallelic inactivation of the NF1 tumor suppressor gene (a germline loss-of-function variant plus a somatic second hit / loss of heterozygosity), which removes the RAS-GTPase activating function of neurofibromin and drives constitutive RAS-MAPK signaling. Tumors are histologically heterogeneous: neoplastic Schwann cells typically represent only a minority of the cellularity, admixed with fibroblasts, perineurial-like cells, mast cells, and macrophages in a collagen-rich, immunosuppressive microenvironment. Major clinical subtypes are localized cutaneous (dermal) neurofibromas, subcutaneous/diffuse neurofibromas, spinal/paraspinal neurofibromas, and plexiform neurofibromas; plexiform lesions are often congenital, grow along multiple nerve fascicles, and are precursor lesions to malignant peripheral nerve sheath tumor (MPNST). This entry models neurofibroma as the tumor entity and is distinct from the Neurofibromatosis type 1 (NF1) clinical syndrome. The MEK1/2 inhibitor selumetinib is approved for symptomatic, inoperable NF1-associated plexiform neurofibromas.

Ask OpenScientist

Ask a research question about Neurofibroma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal dominant (NF1-associated predisposition) HP:0000006

Most neurofibromas arise in the setting of neurofibromatosis type 1, an autosomal dominant tumor-predisposition syndrome with essentially complete penetrance; approximately 50% of NF1 cases are de novo. Individual neurofibromas then form after a somatic second hit inactivates the remaining NF1 allele. Sporadic solitary neurofibromas instead arise from somatic NF1 inactivation without a germline variant.

autosomal dominant inheritance

Show evidence (1 reference)

PMID:35066574 SUPPORT Other

"Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 individuals worldwide."

Establishes the autosomal dominant NF1 predisposition (≈50% de novo) underlying most neurofibromas.

◆

Subtypes

Cutaneous (dermal) neurofibroma

Localized dermal neurofibromas arising from small cutaneous nerves, presenting as soft rubbery skin nodules. They typically emerge around puberty and increase in number through adult life; nearly all adults with NF1 develop them. They do not undergo malignant transformation.

Plexiform neurofibroma

Complex tumors arising along multiple fascicles of large nerves and plexuses, frequently congenital. They occur in roughly 30-50% of NF1 patients, can cause pain, disfigurement, and neurologic or orthopedic morbidity, and carry a lifetime risk of malignant transformation to MPNST.

Subcutaneous / diffuse neurofibroma

Neurofibromas located in the subcutaneous tissue or growing as diffuse, ill-defined plaque-like infiltrations, most often on the trunk, limbs, or head and neck.

Spinal / paraspinal neurofibroma

Neurofibromas arising from spinal nerve roots and paraspinal nerves, which may produce radiculopathy or cord compression and are the predominant subtype generated in many conditional Nf1-knockout mouse models.

⚙

Pathophysiology

Biallelic NF1 Inactivation in Schwann Cell Lineage

Neurofibroma initiation requires loss of both NF1 alleles in a Schwann cell lineage progenitor. In NF1 patients, one germline loss-of-function NF1 variant is inherited and a somatic second hit (loss of heterozygosity) inactivates the remaining wild-type allele, following the classic Knudson two-hit model. Sporadic solitary neurofibromas arise from two somatic NF1 hits in the absence of a germline variant.

Schwann cell precursor CL:0002573

NF1 hgnc:7765

peripheral nervous system UBERON:0000010

Downstream

RAS Pathway Hyperactivation Loss of neurofibromin removes its RAS-GTPase-activating function, de-repressing RAS in the neoplastic Schwann cell lineage.

Impaired Schwann Cell Differentiation NF1 loss alters Schwann cell differentiation in addition to its effect on RAS-driven growth.

Show evidence (1 reference)

PMID:33108355 SUPPORT In Vitro

"NF1-null SLCs formed bona fide neurofibromas with high levels of SOX10 expression"

Isogenic patient-derived hiPSC Schwannian-lineage cells form neurofibromas only when NF1 is biallelically inactivated (NF1-null), establishing that complete NF1 loss in the Schwann cell lineage is required for tumor formation.

RAS Pathway Hyperactivation

Neurofibromin is a RAS-GTPase-activating protein (RAS-GAP) that normally converts active RAS-GTP to inactive RAS-GDP. Its loss leaves RAS in the active GTP-bound state, producing constitutive RAS signal transduction that feeds the downstream RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR effector cascades.

Schwann cell CL:0002573

Ras protein signal transduction GO:0007265 ↑ INCREASED

Downstream

Constitutive MAPK Cascade Activation Active RAS-GTP drives the RAF-MEK-ERK cascade, the principal proliferative output downstream of NF1 loss and the target of MEK inhibitor therapy.

Show evidence (1 reference)

PMID:35066574 SUPPORT Other

"The NF1 gene encodes neurofibromin, a large protein with RAS GTP-ase activating (RAS-GAP) activity, and loss of NF1 results in increased RAS signaling."

Directly states that NF1 loss removes the RAS-GAP activity of neurofibromin and increases RAS signaling.

Constitutive MAPK Cascade Activation

Sustained RAS-GTP signaling constitutively activates the RAF-MEK-ERK (MAPK) cascade, the dominant proliferative signal in NF1-deficient Schwann cells and the molecular target of MEK1/2 inhibitors such as selumetinib.

Schwann cell CL:0002573

MAPK cascade GO:0000165 ↑ INCREASED

Downstream

Schwann Cell Proliferation and Progenitor Expansion MAPK-driven growth signaling promotes proliferation of the neoplastic Schwann cell lineage.

Show evidence (1 reference)

PMID:33108355 SUPPORT In Vitro

"in addition to regulating MAPK-mediated cell growth"

Identifies MAPK-mediated cell growth as a core consequence of NF1 loss in the Schwann cell lineage neurofibroma model.

Impaired Schwann Cell Differentiation

Beyond its effect on RAS-MAPK growth signaling, NF1 loss impairs Schwann cell differentiation, inducing a persistent stem-like state that expands the pool of SOX10+ progenitors competent to initiate a neurofibroma.

Schwann cell precursor CL:0002573

cell differentiation GO:0030154 ↓ DECREASED

Downstream

Schwann Cell Proliferation and Progenitor Expansion The expanded stem-like progenitor pool provides the cells of origin that proliferate to form the tumor.

Show evidence (1 reference)

PMID:33108355 SUPPORT In Vitro

"NF1 loss impaired Schwann cell differentiation by inducing a persistent stem-like state to expand the pool of progenitors required to initiate tumor formation"

Directly supports the differentiation block and progenitor-pool expansion mechanism upstream of tumor initiation.

Schwann Cell Proliferation and Progenitor Expansion

Proliferation of NF1-null Schwann cells and SOX10+ progenitor-like cells generates the neoplastic compartment of the neurofibroma. Inactivation of both Nf1 alleles in Sox10+ cells is sufficient to generate classic nodular cutaneous and plexiform neurofibromas in vivo.

Schwann cell CL:0002573

Schwann cell proliferation GO:0014010 ↑ INCREASED

Downstream

Tumor Microenvironment Remodeling The expanding NF1-null Schwann cell population recruits and reprograms immune and stromal cells, which come to dominate the tumor mass.

Neurofibroma Sustained proliferation of the neoplastic Schwann cell lineage forms the localized (cutaneous, subcutaneous, spinal) neurofibroma.

Plexiform Neurofibroma When initiated in Schwann lineage cells along large nerves and plexuses, the proliferating tumor forms a plexiform neurofibroma.

Malignant Transformation to MPNST A subset of plexiform neurofibromas accumulate additional somatic lesions and progress along the pathway to malignant transformation.

Show evidence (1 reference)

PMID:33108355 SUPPORT Model Organism

"both Nf1 alleles were inactivated in mouse Sox10+ cells, leading to classic nodular cutaneous and plexiform neurofibroma formation that completely recapitulated their human counterparts"

Demonstrates in a genetically engineered mouse model that biallelic Nf1 loss in Sox10+ Schwann lineage cells drives proliferation into cutaneous and plexiform neurofibromas matching human tumors.

Tumor Microenvironment Remodeling

Long after Nf1 loss, neurofibromas recruit and reprogram a complex microenvironment: in human plexiform neurofibromas immune and stromal cells comprise roughly 90% of the tumor, with monocyte recruitment, aberrant macrophage differentiation, fibroblast-driven collagen deposition, and deregulated cell-cell communication (e.g., MIF-CD74/NF-kB). This microenvironment supports tumor growth and immunosuppression and contributes to mass effect, pain, and disfigurement.

macrophage CL:0000235 fibroblast CL:0000057 mast cell CL:0000097

Downstream

Pain Tumor mass, nerve involvement, and the inflammatory microenvironment contribute to neurofibroma-associated pain.

Motor dysfunction Tumor mass effect and peripheral nerve compression/involvement produce motor dysfunction and muscle weakness.

Show evidence (1 reference)

PMID:36134665 SUPPORT Human Clinical

"showed dramatic expansion of immune and stromal cell populations; in corresponding human PNs, the immune and stromal cells comprised 90% of cells"

Single-cell RNA sequencing shows that immune and stromal cells, not Schwann cells, make up the bulk (~90%) of human plexiform neurofibroma cellularity.

Malignant Transformation to MPNST

Plexiform neurofibromas are precursor lesions for malignant peripheral nerve sheath tumor. Transformation follows a stepwise molecular cascade: on the background of biallelic NF1 loss, inactivation of CDKN2A/B yields an atypical neurofibromatous neoplasm of uncertain biological potential (ANNUBP), and subsequent disruption of the polycomb repressive complex 2 (PRC2; SUZ12/EED) with loss of H3K27me3 drives progression to high-grade MPNST.

Schwann cell CL:0002573

CDKN2A hgnc:1787 SUZ12 hgnc:17101

Downstream

Malignant Peripheral Nerve Sheath Tumor Sequential CDKN2A and PRC2 loss in a plexiform neurofibroma drives transformation to malignant peripheral nerve sheath tumor.

Show evidence (1 reference)

PMID:36831419 SUPPORT Other

"Plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) are novel concepts of MPNST precancerous lesions, which revealed sequential mutations in MPNST development."

Establishes plexiform neurofibroma and ANNUBP as sequential precursor lesions in the neurofibroma-to-MPNST malignant progression pathway.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Integument 2

Neurofibroma Neurofibroma HP:0001067

Show evidence (1 reference)

PMID:33108355 SUPPORT In Vitro

"affected patients develop Schwann cell lineage peripheral nerve sheath tumors (neurofibromas)"

Defines neurofibromas as Schwann cell lineage peripheral nerve sheath tumors, the core phenotype of this entry.

Plexiform Neurofibroma Plexiform neurofibroma HP:0009732

Show evidence (1 reference)

PMID:36831419 SUPPORT Other

"Plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) are novel concepts of MPNST precancerous lesions"

Supports the plexiform neurofibroma subtype and its precursor role for malignant transformation.

Musculoskeletal 1

Motor dysfunction Muscle weakness HP:0001324

Show evidence (1 reference)

PMID:32187457 SUPPORT Human Clinical

"The most frequent neurofibroma-related symptoms were disfigurement (44 patients), motor dysfunction (33), and pain (26)."

In the SPRINT trial, motor dysfunction was among the most frequent plexiform-neurofibroma complications (33 of 50 patients).

Constitutional 1

Pain Pain HP:0012531

Show evidence (1 reference)

PMID:32187457 SUPPORT Human Clinical

"The most frequent neurofibroma-related symptoms were disfigurement (44 patients), motor dysfunction (33), and pain (26)."

In the SPRINT trial cohort of symptomatic plexiform neurofibromas, pain was among the most frequent neurofibroma-related symptoms.

Neoplasm 1

Malignant Peripheral Nerve Sheath Tumor Neurofibrosarcoma HP:0100697

Show evidence (1 reference)

PMID:36831419 SUPPORT Other

"Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma with limited therapeutic options and a poor prognosis."

Characterizes MPNST, the malignant tumor that plexiform neurofibromas can transform into.

🧬

Genetic Associations

NF1 (Germline predisposition with biallelic tumor-suppressor loss)

Gene: NF1 hgnc:7765

Show evidence (1 reference)

PMID:35066574 SUPPORT Other

"Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 individuals worldwide."

Establishes NF1 as the autosomal dominant tumor predisposition gene underlying neurofibroma formation.

💊

Medical Actions

Selumetinib

Action: Pharmacotherapy NCIT:C15986

Agent: selumetinib CHEBI:90227

Oral MEK1/2 inhibitor that suppresses the RAF-MEK-ERK signaling driven by NF1 loss. FDA-approved (2020) for pediatric patients with symptomatic, inoperable NF1-associated plexiform neurofibromas; the pivotal phase 2 SPRINT trial showed durable partial responses with pain and quality-of-life benefit.

Mechanism Target:

INHIBITS Constitutive MAPK Cascade Activation — Selumetinib inhibits MEK1/2, blocking the constitutively active RAF-MEK-ERK cascade downstream of NF1 loss.

Show evidence (1 reference)

PMID:32187457 SUPPORT Human Clinical

"A total of 35 patients (70%) had a confirmed partial response as of March 29, 2019, and 28 of these patients had a durable response (lasting ≥1 year)."

SPRINT phase 2 trial result establishing selumetinib efficacy in inoperable plexiform neurofibromas.

Mirdametinib

Action: Pharmacotherapy NCIT:C15986

Agent: mirdametinib NCIT:C52195

Oral MEK inhibitor for NF1-associated symptomatic plexiform neurofibromas, with reported partial responses and improvements in pain and function; acneiform rash is a common class toxicity.

Mechanism Target:

INHIBITS Constitutive MAPK Cascade Activation — Mirdametinib inhibits MEK, blocking the constitutively active RAF-MEK-ERK cascade downstream of NF1 loss.

Show evidence (1 reference)

PMID:40725763 SUPPORT Other

"Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1."

Review supporting MEK inhibitors as a class as targeted therapy for severe NF1 manifestations including plexiform neurofibromas.

Surgical Resection

Action: surgical procedure MAXO:0000004

Operative removal or debulking of symptomatic neurofibromas; the only potentially curative local option, but many plexiform neurofibromas are unresectable and regrowth is common.

Show evidence (1 reference)

PMID:40725763 SUPPORT Other

"Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection."

Describes the central limitations of surgical resection for neurofibromas, motivating medical (MEK inhibitor) therapy.

{ }

Source YAML

click to show

name: Neurofibroma
creation_date: "2026-06-30T00:00:00Z"
category: Neoplastic
disease_term:
  preferred_term: neurofibroma
  term:
    id: MONDO:0016755
    label: neurofibroma
parents:
  - benign peripheral nerve sheath tumor
description: >-
  Neurofibroma is a benign peripheral nerve sheath tumor of the Schwann-cell
  lineage. The neoplastic Schwann cells arise after biallelic inactivation of
  the NF1 tumor suppressor gene (a germline loss-of-function variant plus a
  somatic second hit / loss of heterozygosity), which removes the RAS-GTPase
  activating function of neurofibromin and drives constitutive RAS-MAPK
  signaling. Tumors are histologically heterogeneous: neoplastic Schwann cells
  typically represent only a minority of the cellularity, admixed with
  fibroblasts, perineurial-like cells, mast cells, and macrophages in a
  collagen-rich, immunosuppressive microenvironment. Major clinical subtypes are
  localized cutaneous (dermal) neurofibromas, subcutaneous/diffuse
  neurofibromas, spinal/paraspinal neurofibromas, and plexiform neurofibromas;
  plexiform lesions are often congenital, grow along multiple nerve fascicles,
  and are precursor lesions to malignant peripheral nerve sheath tumor (MPNST).
  This entry models neurofibroma as the tumor entity and is distinct from the
  Neurofibromatosis type 1 (NF1) clinical syndrome. The MEK1/2 inhibitor
  selumetinib is approved for symptomatic, inoperable NF1-associated plexiform
  neurofibromas.
has_subtypes:
  - name: Cutaneous
    display_name: Cutaneous (dermal) neurofibroma
    description: >-
      Localized dermal neurofibromas arising from small cutaneous nerves,
      presenting as soft rubbery skin nodules. They typically emerge around
      puberty and increase in number through adult life; nearly all adults with
      NF1 develop them. They do not undergo malignant transformation.
  - name: Plexiform
    display_name: Plexiform neurofibroma
    description: >-
      Complex tumors arising along multiple fascicles of large nerves and
      plexuses, frequently congenital. They occur in roughly 30-50% of NF1
      patients, can cause pain, disfigurement, and neurologic or orthopedic
      morbidity, and carry a lifetime risk of malignant transformation to MPNST.
  - name: Subcutaneous
    display_name: Subcutaneous / diffuse neurofibroma
    description: >-
      Neurofibromas located in the subcutaneous tissue or growing as diffuse,
      ill-defined plaque-like infiltrations, most often on the trunk, limbs, or
      head and neck.
  - name: Spinal
    display_name: Spinal / paraspinal neurofibroma
    description: >-
      Neurofibromas arising from spinal nerve roots and paraspinal nerves, which
      may produce radiculopathy or cord compression and are the predominant
      subtype generated in many conditional Nf1-knockout mouse models.
pathophysiology:
  - name: Biallelic NF1 Inactivation in Schwann Cell Lineage
    description: >-
      Neurofibroma initiation requires loss of both NF1 alleles in a Schwann
      cell lineage progenitor. In NF1 patients, one germline loss-of-function
      NF1 variant is inherited and a somatic second hit (loss of heterozygosity)
      inactivates the remaining wild-type allele, following the classic Knudson
      two-hit model. Sporadic solitary neurofibromas arise from two somatic NF1
      hits in the absence of a germline variant.
    cell_types:
      - preferred_term: Schwann cell precursor
        term:
          id: CL:0002573
          label: Schwann cell
    genes:
      - preferred_term: NF1
        term:
          id: hgnc:7765
          label: NF1
    gene_products:
      - preferred_term: neurofibromin
        term:
          id: NCIT:C17412
          label: Neurofibromin
    locations:
      - preferred_term: peripheral nervous system
        term:
          id: UBERON:0000010
          label: peripheral nervous system
    evidence:
      - reference: PMID:33108355
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "NF1-null SLCs formed bona fide neurofibromas with high levels of SOX10 expression"
        explanation: >-
          Isogenic patient-derived hiPSC Schwannian-lineage cells form
          neurofibromas only when NF1 is biallelically inactivated (NF1-null),
          establishing that complete NF1 loss in the Schwann cell lineage is
          required for tumor formation.
    downstream:
      - target: RAS Pathway Hyperactivation
        description: >-
          Loss of neurofibromin removes its RAS-GTPase-activating function,
          de-repressing RAS in the neoplastic Schwann cell lineage.
        causal_link_type: DIRECT
      - target: Impaired Schwann Cell Differentiation
        description: >-
          NF1 loss alters Schwann cell differentiation in addition to its effect
          on RAS-driven growth.
        causal_link_type: DIRECT
        evidence:
          - reference: PMID:33108355
            supports: SUPPORT
            evidence_source: IN_VITRO
            snippet: "in addition to regulating MAPK-mediated cell growth, NF1 loss also altered Schwann cell differentiation to promote neurofibroma development"
            explanation: >-
              Directly supports a differentiation-altering effect of NF1 loss
              distinct from its MAPK growth effect.
  - name: RAS Pathway Hyperactivation
    description: >-
      Neurofibromin is a RAS-GTPase-activating protein (RAS-GAP) that normally
      converts active RAS-GTP to inactive RAS-GDP. Its loss leaves RAS in the
      active GTP-bound state, producing constitutive RAS signal transduction
      that feeds the downstream RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR effector
      cascades.
    cell_types:
      - preferred_term: Schwann cell
        term:
          id: CL:0002573
          label: Schwann cell
    biological_processes:
      - preferred_term: Ras protein signal transduction
        modifier: INCREASED
        term:
          id: GO:0007265
          label: Ras protein signal transduction
    evidence:
      - reference: PMID:35066574
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "The NF1 gene encodes neurofibromin, a large protein with RAS GTP-ase activating (RAS-GAP) activity, and loss of NF1 results in increased RAS signaling."
        explanation: >-
          Directly states that NF1 loss removes the RAS-GAP activity of
          neurofibromin and increases RAS signaling.
    downstream:
      - target: Constitutive MAPK Cascade Activation
        description: >-
          Active RAS-GTP drives the RAF-MEK-ERK cascade, the principal
          proliferative output downstream of NF1 loss and the target of MEK
          inhibitor therapy.
        causal_link_type: DIRECT
  - name: Constitutive MAPK Cascade Activation
    description: >-
      Sustained RAS-GTP signaling constitutively activates the RAF-MEK-ERK
      (MAPK) cascade, the dominant proliferative signal in NF1-deficient Schwann
      cells and the molecular target of MEK1/2 inhibitors such as selumetinib.
    cell_types:
      - preferred_term: Schwann cell
        term:
          id: CL:0002573
          label: Schwann cell
    biological_processes:
      - preferred_term: MAPK cascade
        modifier: INCREASED
        term:
          id: GO:0000165
          label: MAPK cascade
    evidence:
      - reference: PMID:33108355
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "in addition to regulating MAPK-mediated cell growth"
        explanation: >-
          Identifies MAPK-mediated cell growth as a core consequence of NF1 loss
          in the Schwann cell lineage neurofibroma model.
    downstream:
      - target: Schwann Cell Proliferation and Progenitor Expansion
        description: >-
          MAPK-driven growth signaling promotes proliferation of the neoplastic
          Schwann cell lineage.
        causal_link_type: DIRECT
  - name: Impaired Schwann Cell Differentiation
    description: >-
      Beyond its effect on RAS-MAPK growth signaling, NF1 loss impairs Schwann
      cell differentiation, inducing a persistent stem-like state that expands
      the pool of SOX10+ progenitors competent to initiate a neurofibroma.
    cell_types:
      - preferred_term: Schwann cell precursor
        term:
          id: CL:0002573
          label: Schwann cell
    biological_processes:
      - preferred_term: cell differentiation
        modifier: DECREASED
        term:
          id: GO:0030154
          label: cell differentiation
    evidence:
      - reference: PMID:33108355
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "NF1 loss impaired Schwann cell differentiation by inducing a persistent stem-like state to expand the pool of progenitors required to initiate tumor formation"
        explanation: >-
          Directly supports the differentiation block and progenitor-pool
          expansion mechanism upstream of tumor initiation.
    downstream:
      - target: Schwann Cell Proliferation and Progenitor Expansion
        description: >-
          The expanded stem-like progenitor pool provides the cells of origin
          that proliferate to form the tumor.
        causal_link_type: DIRECT
  - name: Schwann Cell Proliferation and Progenitor Expansion
    description: >-
      Proliferation of NF1-null Schwann cells and SOX10+ progenitor-like cells
      generates the neoplastic compartment of the neurofibroma. Inactivation of
      both Nf1 alleles in Sox10+ cells is sufficient to generate classic nodular
      cutaneous and plexiform neurofibromas in vivo.
    cell_types:
      - preferred_term: Schwann cell
        term:
          id: CL:0002573
          label: Schwann cell
    biological_processes:
      - preferred_term: Schwann cell proliferation
        modifier: INCREASED
        term:
          id: GO:0014010
          label: Schwann cell proliferation
    evidence:
      - reference: PMID:33108355
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "both Nf1 alleles were inactivated in mouse Sox10+ cells, leading to classic nodular cutaneous and plexiform neurofibroma formation that completely recapitulated their human counterparts"
        explanation: >-
          Demonstrates in a genetically engineered mouse model that biallelic
          Nf1 loss in Sox10+ Schwann lineage cells drives proliferation into
          cutaneous and plexiform neurofibromas matching human tumors.
    downstream:
      - target: Tumor Microenvironment Remodeling
        description: >-
          The expanding NF1-null Schwann cell population recruits and reprograms
          immune and stromal cells, which come to dominate the tumor mass.
        causal_link_type: DIRECT
      - target: Neurofibroma
        description: >-
          Sustained proliferation of the neoplastic Schwann cell lineage forms
          the localized (cutaneous, subcutaneous, spinal) neurofibroma.
        causal_link_type: DIRECT
      - target: Plexiform Neurofibroma
        description: >-
          When initiated in Schwann lineage cells along large nerves and
          plexuses, the proliferating tumor forms a plexiform neurofibroma.
        causal_link_type: DIRECT
      - target: Malignant Transformation to MPNST
        description: >-
          A subset of plexiform neurofibromas accumulate additional somatic
          lesions and progress along the pathway to malignant transformation.
        causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - name: Tumor Microenvironment Remodeling
    description: >-
      Long after Nf1 loss, neurofibromas recruit and reprogram a complex
      microenvironment: in human plexiform neurofibromas immune and stromal
      cells comprise roughly 90% of the tumor, with monocyte recruitment,
      aberrant macrophage differentiation, fibroblast-driven collagen
      deposition, and deregulated cell-cell communication (e.g., MIF-CD74/NF-kB).
      This microenvironment supports tumor growth and immunosuppression and
      contributes to mass effect, pain, and disfigurement.
    cell_types:
      - preferred_term: macrophage
        term:
          id: CL:0000235
          label: macrophage
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
      - preferred_term: mast cell
        term:
          id: CL:0000097
          label: mast cell
    evidence:
      - reference: PMID:36134665
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "showed dramatic expansion of immune and stromal cell populations; in corresponding human PNs, the immune and stromal cells comprised 90% of cells"
        explanation: >-
          Single-cell RNA sequencing shows that immune and stromal cells, not
          Schwann cells, make up the bulk (~90%) of human plexiform
          neurofibroma cellularity.
    downstream:
      - target: Pain
        description: >-
          Tumor mass, nerve involvement, and the inflammatory microenvironment
          contribute to neurofibroma-associated pain.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Motor dysfunction
        description: >-
          Tumor mass effect and peripheral nerve compression/involvement produce
          motor dysfunction and muscle weakness.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Malignant Transformation to MPNST
    description: >-
      Plexiform neurofibromas are precursor lesions for malignant peripheral
      nerve sheath tumor. Transformation follows a stepwise molecular cascade:
      on the background of biallelic NF1 loss, inactivation of CDKN2A/B yields an
      atypical neurofibromatous neoplasm of uncertain biological potential
      (ANNUBP), and subsequent disruption of the polycomb repressive complex 2
      (PRC2; SUZ12/EED) with loss of H3K27me3 drives progression to high-grade
      MPNST.
    cell_types:
      - preferred_term: Schwann cell
        term:
          id: CL:0002573
          label: Schwann cell
    genes:
      - preferred_term: CDKN2A
        term:
          id: hgnc:1787
          label: CDKN2A
      - preferred_term: SUZ12
        term:
          id: hgnc:17101
          label: SUZ12
    evidence:
      - reference: PMID:36831419
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) are novel concepts of MPNST precancerous lesions, which revealed sequential mutations in MPNST development."
        explanation: >-
          Establishes plexiform neurofibroma and ANNUBP as sequential precursor
          lesions in the neurofibroma-to-MPNST malignant progression pathway.
    downstream:
      - target: Malignant Peripheral Nerve Sheath Tumor
        description: >-
          Sequential CDKN2A and PRC2 loss in a plexiform neurofibroma drives
          transformation to malignant peripheral nerve sheath tumor.
        causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
phenotypes:
  - category: Neoplasm
    name: Neurofibroma
    description: >-
      Benign peripheral nerve sheath tumor of the Schwann cell lineage,
      presenting most commonly as cutaneous, subcutaneous, or spinal lesions.
    phenotype_term:
      preferred_term: Neurofibroma
      term:
        id: HP:0001067
        label: Neurofibroma
    evidence:
      - reference: PMID:33108355
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "affected patients develop Schwann cell lineage peripheral nerve sheath tumors (neurofibromas)"
        explanation: >-
          Defines neurofibromas as Schwann cell lineage peripheral nerve sheath
          tumors, the core phenotype of this entry.
  - category: Neoplasm
    name: Plexiform Neurofibroma
    subtype: Plexiform
    description: >-
      Neurofibroma arising along multiple fascicles of large nerves and
      plexuses, frequently congenital, and a precursor to MPNST.
    phenotype_term:
      preferred_term: Plexiform neurofibroma
      term:
        id: HP:0009732
        label: Plexiform neurofibroma
    evidence:
      - reference: PMID:36831419
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) are novel concepts of MPNST precancerous lesions"
        explanation: >-
          Supports the plexiform neurofibroma subtype and its precursor role for
          malignant transformation.
  - category: Symptom
    name: Pain
    description: >-
      Neurofibroma-related pain is a frequent and clinically significant
      symptom, particularly with plexiform neurofibromas, and is a primary
      driver of treatment.
    phenotype_term:
      preferred_term: Pain
      term:
        id: HP:0012531
        label: Pain
    evidence:
      - reference: PMID:32187457
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The most frequent neurofibroma-related symptoms were disfigurement (44 patients), motor dysfunction (33), and pain (26)."
        explanation: >-
          In the SPRINT trial cohort of symptomatic plexiform neurofibromas,
          pain was among the most frequent neurofibroma-related symptoms.
  - category: Symptom
    name: Motor dysfunction
    description: >-
      Motor dysfunction (weakness and reduced strength/range of motion) from
      tumor mass effect and nerve involvement is a frequent plexiform
      neurofibroma complication; SPRINT measured strength improvement with
      selumetinib.
    phenotype_term:
      preferred_term: Motor dysfunction / muscle weakness
      term:
        id: HP:0001324
        label: Muscle weakness
    evidence:
      - reference: PMID:32187457
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The most frequent neurofibroma-related symptoms were disfigurement (44 patients), motor dysfunction (33), and pain (26)."
        explanation: >-
          In the SPRINT trial, motor dysfunction was among the most frequent
          plexiform-neurofibroma complications (33 of 50 patients).
  - category: Neoplasm
    name: Malignant Peripheral Nerve Sheath Tumor
    subtype: Plexiform
    description: >-
      Malignant transformation of a plexiform neurofibroma to an aggressive
      soft-tissue sarcoma (neurofibrosarcoma / MPNST).
    phenotype_term:
      preferred_term: Neurofibrosarcoma
      term:
        id: HP:0100697
        label: Neurofibrosarcoma
    evidence:
      - reference: PMID:36831419
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma with limited therapeutic options and a poor prognosis."
        explanation: >-
          Characterizes MPNST, the malignant tumor that plexiform neurofibromas
          can transform into.
genetic:
  - name: NF1
    association: Germline predisposition with biallelic tumor-suppressor loss
    gene_term:
      preferred_term: NF1
      term:
        id: hgnc:7765
        label: NF1
    notes: >-
      Germline loss-of-function NF1 variants (autosomal dominant; ~50% de novo)
      predispose to neurofibromas, which form after a somatic second hit
      inactivates the remaining allele. NF1 encodes neurofibromin, a RAS-GAP
      tumor suppressor; over 3,000 pathogenic variants are documented, mostly
      truncating.
    evidence:
      - reference: PMID:35066574
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 individuals worldwide."
        explanation: >-
          Establishes NF1 as the autosomal dominant tumor predisposition gene
          underlying neurofibroma formation.
inheritance:
- name: Autosomal dominant (NF1-associated predisposition)
  description: >-
    Most neurofibromas arise in the setting of neurofibromatosis type 1, an
    autosomal dominant tumor-predisposition syndrome with essentially complete
    penetrance; approximately 50% of NF1 cases are de novo. Individual
    neurofibromas then form after a somatic second hit inactivates the
    remaining NF1 allele. Sporadic solitary neurofibromas instead arise from
    somatic NF1 inactivation without a germline variant.
  inheritance_term:
    preferred_term: autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:35066574
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 individuals worldwide."
    explanation: >-
      Establishes the autosomal dominant NF1 predisposition (≈50% de novo)
      underlying most neurofibromas.
prevalence:
  - notes: >-
      Neurofibromas overwhelmingly occur in the setting of NF1, whose pooled
      prevalence is approximately 1 in 3,164 (birth incidence ~1 in 2,662).
      Nearly all adults with NF1 develop cutaneous neurofibromas.
    evidence:
      - reference: PMID:37710322
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Pooled NF1 prevalence was 1 in 3,164 (95%CI: 1 in 2,132-1 in 4,712)."
        explanation: >-
          Systematic review and meta-analysis estimate of NF1 prevalence, the
          predisposing condition for the great majority of neurofibromas.
treatments:
  - name: Selumetinib
    description: >-
      Oral MEK1/2 inhibitor that suppresses the RAF-MEK-ERK signaling driven by
      NF1 loss. FDA-approved (2020) for pediatric patients with symptomatic,
      inoperable NF1-associated plexiform neurofibromas; the pivotal phase 2
      SPRINT trial showed durable partial responses with pain and quality-of-life
      benefit.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: selumetinib
          term:
            id: CHEBI:90227
            label: selumetinib
    target_mechanisms:
      - target: Constitutive MAPK Cascade Activation
        treatment_effect: INHIBITS
        description: >-
          Selumetinib inhibits MEK1/2, blocking the constitutively active
          RAF-MEK-ERK cascade downstream of NF1 loss.
    evidence:
      - reference: PMID:32187457
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "A total of 35 patients (70%) had a confirmed partial response as of March 29, 2019, and 28 of these patients had a durable response (lasting ≥1 year)."
        explanation: >-
          SPRINT phase 2 trial result establishing selumetinib efficacy in
          inoperable plexiform neurofibromas.
  - name: Mirdametinib
    description: >-
      Oral MEK inhibitor for NF1-associated symptomatic plexiform neurofibromas,
      with reported partial responses and improvements in pain and function;
      acneiform rash is a common class toxicity.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: mirdametinib
          term:
            id: NCIT:C52195
            label: Mirdametinib
    target_mechanisms:
      - target: Constitutive MAPK Cascade Activation
        treatment_effect: INHIBITS
        description: >-
          Mirdametinib inhibits MEK, blocking the constitutively active
          RAF-MEK-ERK cascade downstream of NF1 loss.
    evidence:
      - reference: PMID:40725763
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1."
        explanation: >-
          Review supporting MEK inhibitors as a class as targeted therapy for
          severe NF1 manifestations including plexiform neurofibromas.
  - name: Surgical Resection
    description: >-
      Operative removal or debulking of symptomatic neurofibromas; the only
      potentially curative local option, but many plexiform neurofibromas are
      unresectable and regrowth is common.
    therapeutic_modality: SURGERY
    treatment_term:
      preferred_term: surgical procedure
      term:
        id: MAXO:0000004
        label: surgical procedure
    evidence:
      - reference: PMID:40725763
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection."
        explanation: >-
          Describes the central limitations of surgical resection for
          neurofibromas, motivating medical (MEK inhibitor) therapy.
notes: >-
  Modeled as the neurofibroma tumor entity (MONDO:0016755), distinct from the
  Neurofibromatosis type 1 syndrome entry. NCIT cross-reference: NCIT:C3272.

📚

References & Deep Research

Deep Research

Falcon ▸

1. Disease Information

Edison Scientific Literature 62 citations 2026-06-30T09:35:29.859157

1. Disease Information

Overview

Neurofibroma is a benign peripheral nerve sheath tumor (PNST) composed predominantly of Schwann cells, fibroblasts, perineurial-like cells, mast cells, and extracellular matrix, arising in the context of neurofibromatosis type 1 (NF1), the most common tumor predisposition syndrome (sur2022neurofibromatosisinchildren pages 1-2, mo2022neurofibrominandsuppression pages 1-3). NF1 is an autosomal dominant neurocutaneous disorder caused by germline pathogenic variants in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein functioning as a negative regulator of RAS signaling (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3). Neurofibromas represent the hallmark neoplastic manifestation of NF1 and include several histopathologically and clinically distinct subtypes: cutaneous neurofibromas (cNF), plexiform neurofibromas (pNF), subcutaneous neurofibromas, and diffuse neurofibromas (sur2022neurofibromatosisinchildren pages 2-4, yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5).

Key Identifiers

The following table summarizes key disease identifiers and characteristics:

Disease name	MONDO ID	OMIM	Orphanet	ICD-10 / ICD-11	MeSH	Common synonyms	Inheritance pattern	Prevalence	Incidence	Causal gene	Chromosome location	Protein product	Key pathway
Neurofibroma	MONDO:0016755	Not established for neurofibroma as a standalone entity; commonly contextualized within NF1	Not established for isolated neurofibroma in the gathered evidence	ICD-10: D36.1 (benign neoplasm of peripheral nerves and autonomic nervous system); ICD-11: peripheral nerve sheath benign neoplasm category, exact code not established here	MeSH term used for neurofibroma exists, but identifier not established in gathered evidence	Peripheral nerve sheath tumor; cutaneous neurofibroma; dermal neurofibroma; plexiform neurofibroma; diffuse neurofibroma	Usually occurs in the setting of NF1, which is autosomal dominant with many de novo cases; tumor formation follows a somatic second-hit mechanism in NF1-deficient Schwann lineage cells (sur2022neurofibromatosisinchildren pages 1-2, anastasaki2022rasandbeyond pages 2-3)	NF1 pooled prevalence: 1 in 3,164 (95% CI 1 in 2,132-1 in 4,712); nearly all adults with NF1 develop cutaneous neurofibromas, and 30-50% develop plexiform neurofibromas (lee2023incidenceandprevalence pages 1-2, yu2025emergingmechanismand pages 2-4)	NF1 pooled birth incidence: 1 in 2,662 (95% CI 1 in 1,968-1 in 3,601) (lee2023incidenceandprevalence pages 1-2, lee2023incidenceandprevalence pages 2-4)	NF1 (neurofibromin 1) (kitsera2026moleculargeneticsand pages 2-3, mo2022neurofibrominandsuppression pages 1-3, anastasaki2022rasandbeyond pages 2-3)	17q11.2 (sur2022neurofibromatosisinchildren pages 1-2, hussain2024roleoflong pages 3-5)	Neurofibromin, a ~2818 aa RAS-GTPase-activating tumor suppressor (kitsera2026moleculargeneticsand pages 2-3, mo2022neurofibrominandsuppression pages 1-3, anastasaki2022rasandbeyond pages 2-3)	RAS/MAPK is the core dysregulated pathway; PI3K/AKT/mTOR is also activated downstream of NF1 loss (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4, OpenTargets Search: neurofibroma)

Table: This table summarizes key disease identifiers and high-yield characteristics for neurofibroma, emphasizing its close relationship to NF1-associated tumor biology. It is useful as a compact reference for ontology mapping, epidemiology, and molecular annotation.

MONDO ID: MONDO:0016755 (neurofibroma); MONDO:0018975 (neurofibromatosis type 1) (OpenTargets Search: neurofibroma)
OMIM: 162200 (Neurofibromatosis type 1)
ICD-10: D36.1 (Benign neoplasm of peripheral nerves and autonomic nervous system)
MeSH: D009455 (Neurofibroma)
Synonyms: Peripheral nerve sheath tumor, dermal neurofibroma, cutaneous neurofibroma, plexiform neurofibroma, von Recklinghausen disease-associated tumor

2. Etiology

Disease Causal Factors

Neurofibroma formation is driven by biallelic inactivation of the NF1 tumor suppressor gene following a classic Knudson two-hit model. Patients inherit one germline loss-of-function NF1 variant, and tumor initiation requires somatic loss of the remaining wild-type allele (loss of heterozygosity) in Schwann cell lineage progenitors (anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4). Over 3,000 pathogenic NF1 variants have been documented, with more than 80% producing truncated, non-functional neurofibromin protein (lu2025neurofibromatosistype1 pages 2-4).

Genetic Risk Factors

Causal gene: NF1 (neurofibromin 1), chromosome 17q11.2 (kitsera2026moleculargeneticsand pages 2-3, hussain2024roleoflong pages 3-5)
Variant types: Nonsense, frameshift, splice-site, missense mutations, intragenic deletions, whole-gene (microdeletion) deletions (kitsera2026moleculargeneticsand pages 2-3, hussain2024roleoflong pages 3-5)
17q11.2 microdeletion syndrome: Large deletions encompassing the NF1 gene and flanking regions (5–10% of cases), associated with more severe phenotypes including earlier plexiform neurofibroma development and developmental delay (kitsera2026moleculargeneticsand pages 2-3, hussain2024roleoflong pages 3-5, peduto2023neurofibromatosistype1 pages 11-13)
De novo mutations: Approximately 50% of cases arise from de novo NF1 mutations (sur2022neurofibromatosisinchildren pages 1-2)
Modifier genes: SPRED1 has been identified as an NF1-related pathway gene with association scores in OpenTargets (OpenTargets Search: neurofibroma)

Environmental Risk Factors

Radiation exposure is a recognized risk factor for malignant transformation (MPNST development) but is not considered a primary risk factor for benign neurofibroma formation (yao2023malignantperipheralnerve pages 2-4). Nerve injury may serve as a trigger for neurofibroma development, as demonstrated in animal models where sciatic nerve injury induced plexiform neurofibroma formation in NPcis mice (plante2024revisitingthenpcis pages 8-11, plante2024revisitingthenpcis pages 1-2).

3. Phenotypes

Clinical Manifestations of NF1 (with HPO term suggestions)

NF1 presents with multisystem manifestations that appear in an age-dependent manner (lalvani2024neurofibromatosistype1 pages 1-2, imataka2025neurofibromatosistype1 pages 2-4).

Cutaneous/Pigmentary Features: - Café-au-lait macules (CALMs): Present in ~85–95% of patients, appearing at birth or in early infancy as flat tan-brown hyperpigmented lesions (≥6 spots of ≥5 mm pre-pubertal or ≥15 mm post-pubertal). HPO: HP:0007565 (lalvani2024neurofibromatosistype1 pages 1-2, almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 5-7) - Axillary/inguinal freckling (Crowe sign): Present in ~34.8% of patients, typically developing after age 5. HPO: HP:0001067 (almuqbil2024epidemiologyandoutcomes pages 5-7, peduto2023neurofibromatosistype1 pages 2-4)

Ophthalmologic Features: - Iris Lisch nodules: Melanocytic hamartomas present in ~36.4% of patients at a median age of 12 years. HPO: HP:0009737 (almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 5-7) - Optic pathway gliomas: Found in ~36.4% in one multicenter study, typically diagnosed within the first decade of life. HPO: HP:0009734 (almuqbil2024epidemiologyandoutcomes pages 1-2)

Tumor Features: - Cutaneous neurofibromas: Skin tumors originating from cutaneous nerves, forming small rubbery nodules, affecting nearly all adult NF1 patients (>90%). HPO: HP:0001067 (yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5) - Plexiform neurofibromas: Complex tumors arising from large internal nerve plexuses, occurring in 30–60% of NF1 patients, often congenital, with ~15% risk of malignant transformation. HPO: HP:0009732 (yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5, busciglio2025thepathogenesisof pages 1-2)

Skeletal Abnormalities: - Dystrophic scoliosis (up to 30%), sphenoid wing dysplasia, tibial bowing, pseudoarthrosis. HPO: HP:0002650 (scoliosis), HP:0009736 (tibial pseudoarthrosis) (almuqbil2024epidemiologyandoutcomes pages 2-4, imataka2025neurofibromatosistype1 pages 2-4, imataka2025neurofibromatosistype1 pages 4-5)

Neurodevelopmental Features: - Cognitive deficits in approximately 70% of children, including learning disabilities (20.9%), communication disorders (33.8%), ADHD (4.9%), and intellectual disability (10.5%). HPO: HP:0001328 (specific learning disability), HP:0007018 (attention deficit) (almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 5-7, sur2022neurofibromatosisinchildren pages 2-4)

Cardiovascular Features: - Cardiovascular abnormalities in 9.8%, including hypertension, congenital heart defects, and moyamoya syndrome (almuqbil2024epidemiologyandoutcomes pages 1-2, imataka2025neurofibromatosistype1 pages 4-5)

Quality of Life Impact

NF1 imposes significant quality-of-life burden. In a Chinese cohort study, pediatric NF1 patients had EQ-5D-Y utility scores of 0.880 ± 0.13 (VAS 75.38 ± 20.67), while adult patients had EQ-5D-5L utility scores of 0.843 ± 0.17 (VAS 72.32 ± 23.49). Over 50% of both groups reported problems with pain/discomfort, and 42.9–74.3% reported anxiety/depression (liang2024longtermdistressthroughout pages 1-2, liang2024longtermdistressthroughout pages 4-5). Pain occurs at young ages in 41% of patients requiring medication (sur2022neurofibromatosisinchildren pages 2-4).

4. Genetic/Molecular Information

Causal Gene: NF1 (Neurofibromin 1)

HGNC: HGNC:7765
Ensembl: ENSG00000196712
Chromosome: 17q11.2
Protein: Neurofibromin, a 2,818-amino acid protein with RAS-GTPase-activating protein (RAS-GAP) activity (kitsera2026moleculargeneticsand pages 2-3, mo2022neurofibrominandsuppression pages 1-3, lu2025neurofibromatosistype1 pages 2-4)

Pathogenic Variants

The NF1 gene is one of the largest in the human genome (~350 kb, 60 exons). Pathogenic variants span the entire gene, with over 3,000 documented mutations (lu2025neurofibromatosistype1 pages 2-4): - 90–95% are intragenic mutations (nonsense, frameshift, splice-site, missense) (peduto2023neurofibromatosistype1 pages 11-13) - 5–10% involve large deletions (17q11.2 microdeletion syndrome) associated with more severe phenotypes (hussain2024roleoflong pages 3-5, peduto2023neurofibromatosistype1 pages 11-13) - Mutation types include small/large insertions, deletions, chromosome rearrangements, stop mutations, splicing mutations, and amino acid substitutions (hussain2024roleoflong pages 3-5) - Functional consequence: Loss of function (>80% produce truncated protein) (lu2025neurofibromatosistype1 pages 2-4) - Somatic vs germline: Germline heterozygous mutation plus somatic second hit (biallelic inactivation) required for tumor formation (anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4)

Genotype-Phenotype Correlations

Five key genotype-phenotype correlations have been identified (peduto2023neurofibromatosistype1 pages 11-13): - 17q11.2 microdeletion syndrome → more severe disease, earlier tumor onset - Missense variants at codons 844–848 (GRD) → severe phenotype with early tumor development (kitsera2026moleculargeneticsand pages 2-3) - Mutations in the CSRD domain → increased optic glioma risk (mo2022neurofibrominandsuppression pages 1-3, mo2022neurofibrominandsuppression pages 19-21) - p.Met992del → milder phenotype - p.Arg1809 substitutions → Noonan-like features (peduto2023neurofibromatosistype1 pages 11-13)

Malignant Transformation: Neurofibroma-to-MPNST Continuum

Malignant transformation follows a stepwise molecular cascade (busciglio2025thepathogenesisof pages 2-4, busciglio2025thepathogenesisof pages 1-2, busciglio2025thepathogenesisof pages 4-6): 1. Biallelic NF1 inactivation → constitutive RAS activation → benign neurofibroma 2. CDKN2A/B loss → ANNUBP (atypical neurofibromatous neoplasm of uncertain biological potential) 3. PRC2 disruption (SUZ12, EED, or EZH2 mutations/deletions) → H3K27me3 loss → high-grade MPNST

PRC2 inactivation occurs in 70–90% of MPNSTs and represents a defining molecular event, causing global epigenetic dysregulation and enhancer reprogramming (yao2023malignantperipheralnerve pages 2-4, busciglio2025thepathogenesisof pages 6-7). This leads to Schwann cell dedifferentiation, chromosomal instability, and immune-depleted microenvironments (busciglio2025thepathogenesisof pages 14-14, busciglio2025thepathogenesisof pages 10-12).

Epigenetic Information

DNA methylation profiling has emerged as a diagnostic tool for MPNST classification, with distinct methylation clusters corresponding to H3K27me3 status (busciglio2025thepathogenesisof pages 14-14, busciglio2025thepathogenesisof pages 10-12). LncRNAs including ANRIL and H19 show dysregulated expression in NF, influencing RAS/MAPK and JAK/STAT signaling pathways (hussain2024roleoflong pages 3-5).

5. Mechanism / Pathophysiology

Molecular Pathways

Loss of neurofibromin function leads to constitutive activation of multiple oncogenic signaling cascades (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4): - RAS/RAF/MEK/ERK (MAPK) pathway – primary proliferative signal; GO: GO:0000165 (MAPK cascade) - PI3K/AKT/mTOR pathway – survival and growth signaling - cAMP pathway – modulates differentiation and growth - RAS-Rac1 pathway – cytoskeletal regulation and cell migration

Neurofibromin normally converts active RAS-GTP to inactive RAS-GDP through its GAP-related domain (GRD), restraining downstream signaling (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3).

Cellular Processes

Cell of origin: NF1-deficient Schwann cell precursors (SOX10+) from the neural crest lineage; CL: CL:0002573 (Schwann cell precursor) (mo2025humanizedneurofibromamodel pages 1-2)
NF1 loss impairs Schwann cell differentiation, inducing a persistent stem-like state that expands the progenitor pool required for tumor initiation (mo2025humanizedneurofibromamodel pages 1-2)
A glial-to-mesenchymal transition occurs during malignant transformation, with SOX9 identified as a marker of this transition (busciglio2025thepathogenesisof pages 10-12)

Tumor Microenvironment

Single-cell RNA sequencing has revealed the remarkable complexity of the neurofibroma tumor microenvironment (TME): - Schwann cells represent only ~4–10% of tumor cells in pNF, while immune and stromal cells comprise ~90% of human plexiform neurofibromas (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 5-6) - Five distinct SC populations have been identified, including a novel SC progenitor-like (SCP-like) population (kershner2022multiplenf1schwann pages 1-2) - Macrophages (Iba1+CD11b+F4/80+) comprise ~30% of pNF cells with M2-polarized phenotype promoting immunosuppression (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 11-13) - Fibroblasts form the collagen-rich matrix (CD34+), with six distinct populations identified, comprising over 70% of analyzed cells in porcine models (mclean2023singlecellrnasequencing pages 14-15, mclean2023singlecellrnasequencing pages 5-6) - Key cell-cell communication pathways: PROS1-AXL, FGF-FGFR, MIF-CD74, NF-κB, PTN-PTPRZ1, NRXN1-NLGN1, and collagen/laminin-integrin interactions (kershner2022multiplenf1schwann pages 1-2, swanson2025singlecellanalysisof pages 12-15) - Immunosuppressive features: IDO1+/PD-L1+ dendritic cells, M2 macrophages expressing IL-10 and ARG1, and Schwann cell-derived IL-34 promoting CSF1R-mediated M2 polarization (mclean2023singlecellrnasequencing pages 11-13, mclean2023singlecellrnasequencing pages 14-15)

Molecular Profiling

Single-nuclei RNA-sequencing integrated with spatial transcriptomics has identified distinct cellular subpopulations with remarkable inter-sample homogeneity, with the predominant fraction being fibroblast subtypes and NRXN1/NLGN1 receptor-ligand cross-talk predicted between fibroblasts and non-myelinated Schwann cells (swanson2025singlecellanalysisof pages 25-27, swanson2025singlecellanalysisof pages 12-15).

6. Anatomical Structures Affected

Organ Level

Primary: Peripheral nervous system (peripheral nerves, nerve plexuses); UBERON: UBERON:0000010 (peripheral nervous system)
Secondary: Skin (cutaneous neurofibromas), bone, eye, brain, cardiovascular system
Body systems: Nervous, integumentary, skeletal, cardiovascular, endocrine (lalvani2024neurofibromatosistype1 pages 1-2, imataka2025neurofibromatosistype1 pages 2-4)

Tissue and Cell Level

Schwann cells (CL: CL:0002573) – neoplastic driver cells
Fibroblasts (CL: CL:0000057) – major stromal component
Macrophages (CL: CL:0000235) – M2-polarized, immunosuppressive
Mast cells (CL: CL:0000097) – present at low abundance
Endothelial cells, pericytes, T cells – TME components (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 5-6)

Localization

Cutaneous neurofibromas: dermal layer, associated with cutaneous nerves (UBERON: UBERON:0002067, skin of body)
Plexiform neurofibromas: deep nerve plexuses (brachial, lumbosacral, paraspinal); UBERON: UBERON:0001030 (nerve plexus)
Subcutaneous neurofibromas: trunk, arms, face (yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5)

7. Temporal Development

Onset

NF1 has 100% penetrance with age-dependent manifestation (imataka2025neurofibromatosistype1 pages 2-4)
CALMs appear at birth/infancy; freckling after age 5; Lisch nodules by adolescence
Plexiform neurofibromas: Many diagnosed before age 5, suggesting congenital origin (yu2025emergingmechanismand pages 2-4)
Cutaneous neurofibromas: Typically emerge during puberty and increase throughout life (yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5)
Median age at NF1 diagnosis: 11 years (almuqbil2024epidemiologyandoutcomes pages 1-2)

Progression

Benign neurofibromas are generally slow-growing and clinically stable
Plexiform neurofibromas carry 8–15% lifetime risk of malignant transformation to MPNST (imataka2025neurofibromatosistype1 pages 4-5, busciglio2025thepathogenesisof pages 1-2)
MPNST represents the most common cause of death in NF1 patients, with high recurrence rates (30–70%) after surgical resection and resistance to chemotherapy (busciglio2025thepathogenesisof pages 1-2)

Prognosis

Benign neurofibromas: generally good prognosis; significant morbidity from pain, disfigurement, and neurological deficits
MPNST: poor prognosis with median survival of 11 months and 5-year survival rate as low as 6.8% for radiation-induced cases (yao2023malignantperipheralnerve pages 2-4)
High-grade PRC2/CDKN2A-deficient MPNSTs show significantly poorer survival (p = 0.0024) (busciglio2025thepathogenesisof pages 14-14)

8. Inheritance and Population

Epidemiology

A 2023 systematic review and meta-analysis of 12 studies reported (lee2023incidenceandprevalence pages 1-2, lee2023incidenceandprevalence pages 2-4, lee2023incidenceandprevalence pages 4-7): - Pooled NF1 prevalence: 1 in 3,164 (95% CI: 1 in 2,132–1 in 4,712) - Pooled NF1 birth incidence: 1 in 2,662 (95% CI: 1 in 1,968–1 in 3,601) - Screening studies identified higher prevalence (1 in 2,020) compared to medical record-based studies (1 in 4,329), suggesting significant under-recognition

Inheritance

Pattern: Autosomal dominant (sur2022neurofibromatosisinchildren pages 1-2)
Penetrance: 100% (complete) by adulthood (imataka2025neurofibromatosistype1 pages 2-4)
Expressivity: Highly variable, even within families carrying identical mutations (lalvani2024neurofibromatosistype1 pages 1-2)
De novo mutations: ~50% of cases (sur2022neurofibromatosisinchildren pages 1-2)
Sex ratio: No gender predilection reported (sur2022neurofibromatosisinchildren pages 2-4)

9. Diagnostics

Clinical Criteria

The 2021 revised NIH diagnostic criteria for NF1 require ≥2 of the following (almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 2-4, imataka2025neurofibromatosistype1 pages 2-4): - ≥6 CALMs (≥5 mm pre-pubertal, ≥15 mm post-pubertal) - ≥2 neurofibromas of any type or one plexiform neurofibroma - Axillary or inguinal freckling - Optic pathway glioma - ≥2 Lisch nodules or ≥2 choroidal abnormalities - Distinctive osseous lesion (sphenoid dysplasia, tibial bowing/pseudoarthrosis) - Heterozygous pathogenic NF1 variant - First-degree relative with NF1

Genetic Testing

Molecular analysis of the NF1 gene is fundamental for confirming diagnosis, especially in cases with atypical or incomplete clinical features, and for distinguishing from Legius syndrome (SPRED1 mutations) (peduto2023neurofibromatosistype1 pages 2-4). Sequencing approaches include next-generation sequencing panels, whole-exome, or whole-genome sequencing. Differential diagnosis includes Legius syndrome and other RASopathies (peduto2023neurofibromatosistype1 pages 2-4).

Imaging

Volumetric MRI is the standard for assessment of plexiform neurofibromas, used for both initial evaluation and monitoring treatment response (≥20% volume decrease defines partial response) (armstrong2023treatmentdecisionsand pages 2-4).

Biomarkers for Malignant Transformation

Circulating tumor DNA (ctDNA) analyses reveal distinctive copy number variations and methylation patterns that can detect malignant transformation (busciglio2025thepathogenesisof pages 1-2). H3K27me3 loss by immunohistochemistry is a highly sensitive marker for MPNST pathogenesis (yao2023malignantperipheralnerve pages 2-4). A 50-protein plasma panel has been identified that accurately distinguishes MPNST from premalignant tumors (from single-cell TME profiling-informed proteomic studies) (OpenTargets Search: neurofibroma).

10. Treatment

Current Treatment Landscape

The following table summarizes the therapeutic landscape for neurofibroma:

Therapy	Class / mechanism	Main indication in neurofibroma	Key clinical results	FDA approval status	Notable adverse effects / limitations
Selumetinib	MEK1/2 inhibitor; suppresses RAF-MEK-ERK signaling downstream of NF1 loss	Symptomatic, inoperable NF1-associated plexiform neurofibromas (PN), primarily pediatric	Phase II: 68% confirmed partial response (34/50), median best tumor volume reduction 27.9%; Phase I/II long-term follow-up: 70% overall confirmed partial response with durable pain improvement; systematic review cites ~68-71% partial response (armstrong2023treatmentdecisionsand pages 2-4, souza2022clinicaltrialstargeting pages 5-6, souza2022clinicaltrialstargeting pages 9-10, imataka2025neurofibromatosistype1 pages 9-11)	FDA approved in 2020 for pediatric patients with symptomatic, inoperable NF1-PN; also supported by approval-linked Open Targets evidence for MAP2K1/MAP2K2 (souza2022clinicaltrialstargeting pages 5-6, armstrong2023treatmentdecisionsand pages 2-4, OpenTargets Search: neurofibroma)	Rash, vomiting, diarrhea, nausea, fatigue; grade 3 adverse events reported; cardiomyopathy and ocular toxicity require monitoring; prolonged therapy often needed because tumors may regrow after discontinuation (imataka2025neurofibromatosistype1 pages 12-13, imataka2025neurofibromatosistype1 pages 9-11)
Mirdametinib	MEK inhibitor	NF1-associated plexiform neurofibromas, including symptomatic/inoperable disease	Partial response reported in 42-50% of patients, with improvements in pain and functioning in trial summaries/reviews (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7, souza2022clinicaltrialstargeting pages 9-10)	FDA approved in 2024 for NF1 with symptomatic plexiform neurofibromas according to current treatment reviews and user-specified latest landscape; active studies ongoing (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7)	Acneiform rash very common (~94.7% in one study summary), nausea, diarrhea; some patients required dose reductions; class toxicities similar to other MEK inhibitors (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7)
Trametinib	MEK inhibitor	Investigational treatment for NF1-associated plexiform neurofibromas, including pediatric populations	Studied in children aged 1-17 years; efficacy signal noted in reviews, but no pivotal response rate as established as selumetinib in the cited evidence (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4)	Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence	Dermatologic and gastrointestinal class toxicities expected; long-term comparative efficacy remains uncertain (armstrong2023treatmentdecisionsand pages 6-7, imataka2025neurofibromatosistype1 pages 7-9)
Binimetinib	MEK inhibitor	Investigational therapy for NF1-associated plexiform neurofibromas	Included in ongoing/previous clinical development programs for NF1-PN; no definitive response rate provided in the gathered evidence excerpt (souza2022clinicaltrialstargeting pages 5-6, armstrong2023treatmentdecisionsand pages 2-4)	Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence	MEK inhibitor class toxicities likely, including rash and gastrointestinal events; evidence still emerging (souza2022clinicaltrialstargeting pages 5-6, imataka2025neurofibromatosistype1 pages 7-9)
Cabozantinib	Multikinase tyrosine kinase inhibitor	Unresectable, progressive, or symptomatic NF1-associated plexiform neurofibromas, especially adolescents/adults	Partial response in 42% of patients; associated with pain reduction in reported studies/reviews (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7, souza2022clinicaltrialstargeting pages 9-10)	Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence	Fatigue, gastrointestinal effects, hypothyroidism, dermatologic toxicities; used investigationally (armstrong2023treatmentdecisionsand pages 6-7)
NFX-179 topical gel	Topical, metabolically labile MEK inhibitor	Cutaneous neurofibromas (cNF) in NF1	Phase 2a: dose-dependent MEK inhibition with 47% reduction in p-ERK at 0.5%; 20% of treated cNFs had >=50% volume reduction vs 6% with vehicle after 28 days (OpenTargets Search: neurofibroma)	Not FDA approved in cited evidence	No local or systemic toxicities observed during short treatment period; systemic levels remained <1 ng/mL; durability still under study (OpenTargets Search: neurofibroma)
Imatinib	Tyrosine kinase inhibitor	Investigational treatment for plexiform neurofibromas	Reported median tumor volume reduction of 26.5% in review summaries; explored before MEK inhibitors became standard (imataka2025neurofibromatosistype1 pages 7-9, imataka2025neurofibromatosistype1 pages 9-11)	Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence	Limited efficacy compared with MEK inhibitors; off-target toxicities typical of TKIs; not current standard of care (imataka2025neurofibromatosistype1 pages 7-9)
Surgical resection / debulking	Operative removal of tumor; potentially curative if complete excision feasible	Symptomatic cutaneous or plexiform neurofibromas causing pain, neurologic deficit, disfigurement, airway compromise, or orthopedic complications	Remains standard and only potentially curative local option, but many PN are unresectable; regrowth after surgery ranges ~20-68% depending on extent of resection (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4)	Standard clinical practice, not an FDA-regulated drug approval question	Risks include bleeding, neurologic injury, incomplete resection, recurrence/regrowth, and anatomic inaccessibility (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4, imataka2025neurofibromatosistype1 pages 7-9)
Gene therapy approaches	Experimental gene restoration / editing strategies, including AAV-based NF1 restoration concepts	Future disease-modifying therapy for NF1-associated neurofibromas and related tumors	Preclinical/early translational only in gathered evidence; recent reviews highlight AAV-based gene therapy, gene-targeted approaches, and humanized/iPSC models to enable testing (lu2025neurofibromatosistype1 pages 2-4, mo2025humanizedneurofibromamodel pages 1-2)	No FDA-approved gene therapy for neurofibroma in cited evidence	Major limitations include delivery of the large NF1 gene, durability, tumor heterogeneity, and need for robust preclinical validation (lu2025neurofibromatosistype1 pages 2-4, mo2025humanizedneurofibromamodel pages 1-2)

Table: This table summarizes current and emerging treatments for neurofibroma, especially NF1-associated plexiform and cutaneous neurofibromas. It highlights mechanisms, indications, response rates, approval status, and key safety considerations to support knowledge base curation and comparative review.

Pharmacotherapy

Selumetinib (KOSELUGO®) is the first FDA-approved medical therapy for NF1-associated symptomatic, inoperable plexiform neurofibromas in pediatric patients aged ≥2 years. The pivotal SPRINT trial demonstrated a 68% confirmed partial response rate (34/50 patients) with median tumor volume reduction of 27.9% from baseline (armstrong2023treatmentdecisionsand pages 2-4). Long-term follow-up showed durable responses: 70% overall confirmed partial response with sustained pain improvement beyond 5 years of treatment (imataka2025neurofibromatosistype1 pages 9-11). Quality of life improved in 70% and pain reduced in 85% of patients with baseline pain (imataka2025neurofibromatosistype1 pages 9-11). The standard dosage is 25 mg/m² orally twice daily (imataka2025neurofibromatosistype1 pages 9-11).

Mirdametinib achieved 42–50% partial response rates with significant improvements in pain and functioning (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7).

NFX-179 Topical Gel, a metabolically labile MEK inhibitor for cutaneous neurofibromas, demonstrated dose-dependent MEK inhibition with a 47% decrease in p-ERK levels in a phase 2a trial, with excellent safety and no systemic toxicity (OpenTargets Search: neurofibroma).

Drug Targets (OpenTargets)

OpenTargets analysis identified the following validated drug targets for neurofibroma (MONDO:0016755) with association scores (OpenTargets Search: neurofibroma): - NF1 (neurofibromin 1) – score 0.699 - MAP2K1 (MEK1) – score 0.535 (clinical stage: APPROVAL) - MAP2K2 (MEK2) – score 0.532 (clinical stage: APPROVAL) - SPRED1 – score 0.480 (NF1-related pathway)

Surgical and Interventional

Surgical resection remains the only potentially curative option but is limited by incomplete resectability, with regrowth rates of 20–68% depending on extent of resection (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4). MAXO term: MAXO:0000004 (surgical procedure).

Experimental Therapies and Clinical Trials

The following table summarizes active recruiting clinical trials:

NCT number	Brief study title	Phase	Intervention type	Target enrollment	Status
NCT05199376	Percutaneous cryotherapy for plexiform/unresectable neurofibromas in NF1	N/A	Interventional; cryotherapy	30	Recruiting (OpenTargets Search: neurofibroma)
NCT07407803	TQ-B3234 capsules for symptomatic, non-surgical NF1-associated plexiform neurofibromas	Phase 3	Interventional; small-molecule drug	177	Recruiting (OpenTargets Search: neurofibroma)
NCT07102394	IMLYGIC for cutaneous neurofibromas in adults with NF1	Phase 1	Interventional; oncolytic viral therapy	10	Recruiting (OpenTargets Search: neurofibroma)
NCT05331105	HL-085 in adults with NF1 and inoperable plexiform neurofibromas	Phase 2	Interventional; small-molecule drug	70	Recruiting (OpenTargets Search: neurofibroma)
NCT06188741	Selumetinib for prevention of plexiform neurofibroma growth in NF1	Phase 2	Interventional; MEK inhibitor	200	Recruiting (OpenTargets Search: neurofibroma)
NCT06159166	Mirdametinib monotherapy in adults with NF1 and cutaneous neurofibromas	Phase 1/2	Interventional; MEK inhibitor	24	Recruiting (OpenTargets Search: neurofibroma)
NCT06961565	PAS-004 in adults with NF1 and plexiform neurofibromas	Phase 1	Interventional; investigational drug	56	Recruiting (OpenTargets Search: neurofibroma)
NCT06515860	NF1 Tumor Early Detection Study	Observational	Observational; early detection/biomarker study	1000	Recruiting (OpenTargets Search: neurofibroma)

Table: This table summarizes active/recruiting neurofibroma-related clinical studies identified in the search, highlighting trial phase, intervention type, enrollment, and current status. It is useful for quickly surveying the present translational and therapeutic pipeline in NF1-associated neurofibroma.

Emerging therapeutic strategies under investigation include AAV-based gene therapy for NF1 restoration, oncolytic herpes simplex virus (oHSV) therapy, CAR-T cell therapy targeting NF1-associated tumors, and combination strategies such as MEK + PAK inhibition for treatment-resistant tumors (lu2025neurofibromatosistype1 pages 2-4). Prolonged MEK inhibition induces compensatory phosphorylation of MEK and AKT, supporting the rationale for combination strategies (OpenTargets Search: neurofibroma).

11. Prevention

Primary Prevention

No primary prevention exists for NF1-associated neurofibromas given the genetic etiology. Genetic counseling is recommended for affected families. MAXO term: MAXO:0000127 (genetic counseling).

Secondary Prevention

Surveillance protocols: Regular clinical examinations, ophthalmologic assessments, developmental screening, and neuroimaging per age-appropriate guidelines (lalvani2024neurofibromatosistype1 pages 1-2, almuqbil2024epidemiologyandoutcomes pages 2-4)
Selumetinib for prevention: An active Phase 2 trial (NCT06188741) is investigating selumetinib for prevention of plexiform neurofibroma growth in NF1 (OpenTargets Search: neurofibroma)
Early detection: An NF1 Tumor Early Detection Study (NCT06515860) with 1,000 planned participants is currently recruiting (OpenTargets Search: neurofibroma)
Liquid biopsy: ctDNA-based approaches for early detection of malignant transformation are under development (busciglio2025thepathogenesisof pages 1-2)

Screening

Cascade genetic testing of first-degree relatives is recommended. Standardized genotyping enables early identification of high-risk genotypes (e.g., 17q11.2 microdeletion) for intensified surveillance (kitsera2026moleculargeneticsand pages 2-3, peduto2023neurofibromatosistype1 pages 11-13).

12. Model Organisms

Mouse Models

Multiple genetically engineered mouse models recapitulate aspects of human neurofibroma (plante2024revisitingthenpcis pages 8-11, plante2024revisitingthenpcis pages 1-2, plante2024revisitingthenpcis pages 11-12, plante2024revisitingthenpcis pages 2-4, mo2025humanizedneurofibromamodel pages 1-2): - Conditional Nf1 knockout models: Tissue-specific Cre recombinase (Krox20-Cre, P0-Cre, DhhCre, Hoxb7-Cre) combined with Nf1 flox mice generate para-spinal neurofibromas in 6–12 months - NPcis model: The most widely used MPNST model; develops MPNSTs in 3–6 months with 30% penetrance. Intentional sciatic nerve injury converts it into a plexiform neurofibroma model within 1–6 months with 50% penetrance (plante2024revisitingthenpcis pages 8-11, plante2024revisitingthenpcis pages 11-12, plante2024revisitingthenpcis pages 2-4) - Sox10-Cre Nf1 knockout: Inactivation of both Nf1 alleles in Sox10+ cells generates classic nodular cutaneous and plexiform neurofibromas that completely recapitulate human counterparts – described as the first genetically engineered mouse model of nodular cutaneous neurofibroma (mo2025humanizedneurofibromamodel pages 1-2)

Porcine Models

Genetically engineered NF1-mutant minipigs closely resemble human neurofibromas histologically and contain all known cellular components of their human counterparts, including Schwann cells, fibroblasts, immune cells, and vascular elements. These models are used for single-cell transcriptomic profiling and preclinical drug testing (mclean2023singlecellrnasequencing pages 16-17, mclean2023singlecellrnasequencing pages 1-2).

iPSC-Derived Models

Patient-specific NF1-mutant human induced pluripotent stem cells (hiPSCs) differentiated into Schwannian lineage cells (SLCs) form bona fide neurofibromas upon mouse sciatic nerve implantation when NF1-null, while wild-type and heterozygous cells do not (mo2025humanizedneurofibromamodel pages 1-2).

Model Limitations

Current tissue-specific knockout models primarily recapitulate para-spinal neurofibromas (a rare subtype in humans), and de novo rapid MPNST development in mice does not accurately mirror the slow human neurofibroma-to-MPNST progression (plante2024revisitingthenpcis pages 8-11, mclean2023singlecellrnasequencing pages 1-2).

13. Summary

Neurofibroma represents the defining neoplastic manifestation of NF1, driven by biallelic inactivation of the NF1 tumor suppressor gene and constitutive RAS/MAPK pathway activation. The disease has undergone a therapeutic revolution with the approval of MEK inhibitors, particularly selumetinib (68–71% partial response rate) and mirdametinib (42–50% partial response rate) for inoperable plexiform neurofibromas (souza2022clinicaltrialstargeting pages 5-6, armstrong2023treatmentdecisionsand pages 2-4). Single-cell transcriptomic studies have revealed the remarkable complexity of the neurofibroma tumor microenvironment, with immune and stromal cells comprising ~90% of tumor cellularity and multiple immunosuppressive mechanisms identified (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 11-13, mclean2023singlecellrnasequencing pages 14-15). The malignant transformation pathway from neurofibroma to MPNST involves sequential loss of CDKN2A and PRC2 components, representing actionable biomarkers for early detection and therapeutic targeting (busciglio2025thepathogenesisof pages 2-4, busciglio2025thepathogenesisof pages 1-2). Ongoing clinical trials are exploring prevention strategies, topical MEK inhibitors for cutaneous neurofibromas, and gene therapy approaches, representing a rapidly evolving therapeutic landscape for this complex tumor predisposition syndrome.

References

(sur2022neurofibromatosisinchildren pages 1-2): Maria Lucia Sur, Ionel Armat, Genel Sur, Diana-Cristina Pop, Gabriel Samasca, Iulia Lupan, Teodora-Larisa Timis, Ioan-Alexandru Florian, and Daniel Sur. Neurofibromatosis in children: actually and perspectives. Children, 9:40, Jan 2022. URL: https://doi.org/10.3390/children9010040, doi:10.3390/children9010040. This article has 19 citations.
(mo2022neurofibrominandsuppression pages 1-3): Juan Mo, Stefanie L. Moye, Renee M. McKay, and Lu Q. Le. Neurofibromin and suppression of tumorigenesis: beyond the gap. Oncogene, 41:1235-1251, Jan 2022. URL: https://doi.org/10.1038/s41388-021-02156-y, doi:10.1038/s41388-021-02156-y. This article has 99 citations and is from a domain leading peer-reviewed journal.
(kitsera2026moleculargeneticsand pages 2-3): N.I. Kitsera, M.I. Drobchak, M.V. Bondarenko, R.V. Kozovyi, L.Ye. Kovalchuk, O.I. Dorosh, and I.L. Kozova. Molecular genetics and clinical spectrum of neurofibromatosis type 1 in patients: a case-based review. CHILD`S HEALTH, 21:49-59, Mar 2026. URL: https://doi.org/10.22141/2224-0551.21.1.2026.1939, doi:10.22141/2224-0551.21.1.2026.1939. This article has 0 citations.
(anastasaki2022rasandbeyond pages 2-3): Corina Anastasaki, Paola Orozco, and David H. Gutmann. Ras and beyond: the many faces of the neurofibromatosis type 1 protein. Disease Models & Mechanisms, Feb 2022. URL: https://doi.org/10.1242/dmm.049362, doi:10.1242/dmm.049362. This article has 108 citations and is from a domain leading peer-reviewed journal.
(sur2022neurofibromatosisinchildren pages 2-4): Maria Lucia Sur, Ionel Armat, Genel Sur, Diana-Cristina Pop, Gabriel Samasca, Iulia Lupan, Teodora-Larisa Timis, Ioan-Alexandru Florian, and Daniel Sur. Neurofibromatosis in children: actually and perspectives. Children, 9:40, Jan 2022. URL: https://doi.org/10.3390/children9010040, doi:10.3390/children9010040. This article has 19 citations.
(yu2025emergingmechanismand pages 2-4): Xuan Yu, Yi-Hui Gu, Jun Liu, Jing-Xuan Huang, Qingfeng Li, and Zhichao Wang. Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: advancing insights into tumor development. Neuro-Oncology Advances, Feb 2025. URL: https://doi.org/10.1093/noajnl/vdaf040, doi:10.1093/noajnl/vdaf040. This article has 2 citations and is from a peer-reviewed journal.
(imataka2025neurofibromatosistype1 pages 4-5): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.
(lee2023incidenceandprevalence pages 1-2): Tin-Suet Joan Lee, Meera Chopra, Raymond H. Kim, Patricia C. Parkin, and Carolina Barnett-Tapia. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02911-2, doi:10.1186/s13023-023-02911-2. This article has 171 citations and is from a peer-reviewed journal.
(lee2023incidenceandprevalence pages 2-4): Tin-Suet Joan Lee, Meera Chopra, Raymond H. Kim, Patricia C. Parkin, and Carolina Barnett-Tapia. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02911-2, doi:10.1186/s13023-023-02911-2. This article has 171 citations and is from a peer-reviewed journal.
(hussain2024roleoflong pages 3-5): Md Sadique Hussain, Somya Sharma, Alka Kumari, Almaz Kamran, Gurusha Bahl, Ajay Singh Bisht, Ayesha Sultana, Sumel Ashique, Prasanna Srinivasan Ramalingam, and Sivakumar Arumugam. Role of long non-coding rnas in neurofibromatosis and schwannomatosis: pathogenesis and therapeutic potential. Epigenomics, 16:1-12, Nov 2024. URL: https://doi.org/10.1080/17501911.2024.2430170, doi:10.1080/17501911.2024.2430170. This article has 15 citations and is from a peer-reviewed journal.
(lu2025neurofibromatosistype1 pages 2-4): Yuqing Lu, Manzhu Xu, Xiaojun Chen, Huazhen Xu, Nihao Sun, Karis E. Weisgerber, and Ren-Yuan Bai. Neurofibromatosis type 1: genetic mechanisms and advances in therapeutic innovation. Cancers, 17:3788, Nov 2025. URL: https://doi.org/10.3390/cancers17233788, doi:10.3390/cancers17233788. This article has 3 citations.
(OpenTargets Search: neurofibroma): Open Targets Query (neurofibroma, 42 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(peduto2023neurofibromatosistype1 pages 11-13): Cristina Peduto, Mariateresa Zanobio, Vincenzo Nigro, Silverio Perrotta, Giulio Piluso, and Claudia Santoro. Neurofibromatosis type 1: pediatric aspects and review of genotype–phenotype correlations. Cancers, 15:1217, Feb 2023. URL: https://doi.org/10.3390/cancers15041217, doi:10.3390/cancers15041217. This article has 88 citations.
(yao2023malignantperipheralnerve pages 2-4): Chengjun Yao, Haiying Zhou, Yanzhao Dong, Ahmad Alhaskawi, Sohaib Hasan Abdullah Ezzi, Zewei Wang, Jingtian Lai, Vishnu Goutham Kota, Mohamed Hasan Abdulla Hasan Abdulla, and Hui Lu. Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management. Cancers, 15:1077, Feb 2023. URL: https://doi.org/10.3390/cancers15041077, doi:10.3390/cancers15041077. This article has 129 citations.
(plante2024revisitingthenpcis pages 8-11): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.
(plante2024revisitingthenpcis pages 1-2): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.
(lalvani2024neurofibromatosistype1 pages 1-2): Shaan Lalvani and Rebecca Brown. Neurofibromatosis type 1: optimizing management with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 17:1803-1817, Apr 2024. URL: https://doi.org/10.2147/jmdh.s362791, doi:10.2147/jmdh.s362791. This article has 31 citations and is from a peer-reviewed journal.
(imataka2025neurofibromatosistype1 pages 2-4): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.
(almuqbil2024epidemiologyandoutcomes pages 1-2): Mohammed Almuqbil, Fatimah Alshaikh, Waleed Altwaijri, Duaa Baarmah, Raid Hommady, Maryam Alshaikh, Fares Alammari, Meshal Alhussain, Reem Almotawa, Faris Alqarni, Amna Kashgari, Rayan Alkhodair, Jumanah Alkhater, Lujeen Alkhater, Sawsan Alharthi, Mada Alsadi, and Ahmed AlRumayyan. Epidemiology and outcomes of neurofibromatosis type 1 (nf-1): multicenter tertiary experience. Journal of Multidisciplinary Healthcare, 17:1303-1314, Mar 2024. URL: https://doi.org/10.2147/jmdh.s454921, doi:10.2147/jmdh.s454921. This article has 14 citations and is from a peer-reviewed journal.
(almuqbil2024epidemiologyandoutcomes pages 5-7): Mohammed Almuqbil, Fatimah Alshaikh, Waleed Altwaijri, Duaa Baarmah, Raid Hommady, Maryam Alshaikh, Fares Alammari, Meshal Alhussain, Reem Almotawa, Faris Alqarni, Amna Kashgari, Rayan Alkhodair, Jumanah Alkhater, Lujeen Alkhater, Sawsan Alharthi, Mada Alsadi, and Ahmed AlRumayyan. Epidemiology and outcomes of neurofibromatosis type 1 (nf-1): multicenter tertiary experience. Journal of Multidisciplinary Healthcare, 17:1303-1314, Mar 2024. URL: https://doi.org/10.2147/jmdh.s454921, doi:10.2147/jmdh.s454921. This article has 14 citations and is from a peer-reviewed journal.
(peduto2023neurofibromatosistype1 pages 2-4): Cristina Peduto, Mariateresa Zanobio, Vincenzo Nigro, Silverio Perrotta, Giulio Piluso, and Claudia Santoro. Neurofibromatosis type 1: pediatric aspects and review of genotype–phenotype correlations. Cancers, 15:1217, Feb 2023. URL: https://doi.org/10.3390/cancers15041217, doi:10.3390/cancers15041217. This article has 88 citations.
(busciglio2025thepathogenesisof pages 1-2): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.
(almuqbil2024epidemiologyandoutcomes pages 2-4): Mohammed Almuqbil, Fatimah Alshaikh, Waleed Altwaijri, Duaa Baarmah, Raid Hommady, Maryam Alshaikh, Fares Alammari, Meshal Alhussain, Reem Almotawa, Faris Alqarni, Amna Kashgari, Rayan Alkhodair, Jumanah Alkhater, Lujeen Alkhater, Sawsan Alharthi, Mada Alsadi, and Ahmed AlRumayyan. Epidemiology and outcomes of neurofibromatosis type 1 (nf-1): multicenter tertiary experience. Journal of Multidisciplinary Healthcare, 17:1303-1314, Mar 2024. URL: https://doi.org/10.2147/jmdh.s454921, doi:10.2147/jmdh.s454921. This article has 14 citations and is from a peer-reviewed journal.
(liang2024longtermdistressthroughout pages 1-2): Wanxian Liang, Shihuan Cao, Yusi Suo, Lining Zhang, Lujia Yang, Ping Wang, Hanfei Wang, Hanfei Wang, Guannan Bai, Qingnan Li, Jiayin Zheng, and Xuejing Jin. Long-term distress throughout one’s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in china. Frontiers in Public Health, Aug 2024. URL: https://doi.org/10.3389/fpubh.2024.1398803, doi:10.3389/fpubh.2024.1398803. This article has 4 citations.
(liang2024longtermdistressthroughout pages 4-5): Wanxian Liang, Shihuan Cao, Yusi Suo, Lining Zhang, Lujia Yang, Ping Wang, Hanfei Wang, Hanfei Wang, Guannan Bai, Qingnan Li, Jiayin Zheng, and Xuejing Jin. Long-term distress throughout one’s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in china. Frontiers in Public Health, Aug 2024. URL: https://doi.org/10.3389/fpubh.2024.1398803, doi:10.3389/fpubh.2024.1398803. This article has 4 citations.
(mo2022neurofibrominandsuppression pages 19-21): Juan Mo, Stefanie L. Moye, Renee M. McKay, and Lu Q. Le. Neurofibromin and suppression of tumorigenesis: beyond the gap. Oncogene, 41:1235-1251, Jan 2022. URL: https://doi.org/10.1038/s41388-021-02156-y, doi:10.1038/s41388-021-02156-y. This article has 99 citations and is from a domain leading peer-reviewed journal.
(busciglio2025thepathogenesisof pages 2-4): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.
(busciglio2025thepathogenesisof pages 4-6): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.
(busciglio2025thepathogenesisof pages 6-7): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.
(busciglio2025thepathogenesisof pages 14-14): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.
(busciglio2025thepathogenesisof pages 10-12): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.
(mo2025humanizedneurofibromamodel pages 1-2): Juan Mo, Corina Anastasaki, Zhiguo Chen, Tracey Shipman, Jason Papke, Kevin Yin, David H. Gutmann, and Lu Q. Le. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. Journal of Clinical Investigation, Jan 2025. URL: https://doi.org/10.1172/jci139807, doi:10.1172/jci139807. This article has 81 citations and is from a highest quality peer-reviewed journal.
(kershner2022multiplenf1schwann pages 1-2): Leah J. Kershner, Kwangmin Choi, Jianqiang Wu, Xiyuan Zhang, Melissa Perrino, Nathan Salomonis, Jack F. Shern, and Nancy Ratner. Multiple nf1 schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight, Sep 2022. URL: https://doi.org/10.1172/jci.insight.154513, doi:10.1172/jci.insight.154513. This article has 60 citations and is from a domain leading peer-reviewed journal.
(mclean2023singlecellrnasequencing pages 5-6): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.
(mclean2023singlecellrnasequencing pages 11-13): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.
(mclean2023singlecellrnasequencing pages 14-15): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.
(swanson2025singlecellanalysisof pages 12-15): Grace M Swanson, Marcia Arenas-Hernandez, and Katherine Gurdziel. Single-cell analysis of nf1 -expressing and nf1 -deficient schwann and fibroblast cells reveals divergent neurofibroma programs. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.26.677858, doi:10.1101/2025.09.26.677858. This article has 0 citations.
(swanson2025singlecellanalysisof pages 25-27): Grace M Swanson, Marcia Arenas-Hernandez, and Katherine Gurdziel. Single-cell analysis of nf1 -expressing and nf1 -deficient schwann and fibroblast cells reveals divergent neurofibroma programs. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.26.677858, doi:10.1101/2025.09.26.677858. This article has 0 citations.
(lee2023incidenceandprevalence pages 4-7): Tin-Suet Joan Lee, Meera Chopra, Raymond H. Kim, Patricia C. Parkin, and Carolina Barnett-Tapia. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02911-2, doi:10.1186/s13023-023-02911-2. This article has 171 citations and is from a peer-reviewed journal.
(armstrong2023treatmentdecisionsand pages 2-4): Amy E. Armstrong, Allan J. Belzberg, John R. Crawford, Angela C. Hirbe, and Zhihong J. Wang. Treatment decisions and the use of mek inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer, Jun 2023. URL: https://doi.org/10.1186/s12885-023-10996-y, doi:10.1186/s12885-023-10996-y. This article has 97 citations and is from a peer-reviewed journal.
(souza2022clinicaltrialstargeting pages 5-6): Gabriel Roman Souza, Ahmed Abdalla, and Daruka Mahadevan. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-oncology Advances, Jan 2022. URL: https://doi.org/10.1093/noajnl/vdac005, doi:10.1093/noajnl/vdac005. This article has 18 citations and is from a peer-reviewed journal.
(souza2022clinicaltrialstargeting pages 9-10): Gabriel Roman Souza, Ahmed Abdalla, and Daruka Mahadevan. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-oncology Advances, Jan 2022. URL: https://doi.org/10.1093/noajnl/vdac005, doi:10.1093/noajnl/vdac005. This article has 18 citations and is from a peer-reviewed journal.
(imataka2025neurofibromatosistype1 pages 9-11): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.
(imataka2025neurofibromatosistype1 pages 12-13): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.
(armstrong2023treatmentdecisionsand pages 6-7): Amy E. Armstrong, Allan J. Belzberg, John R. Crawford, Angela C. Hirbe, and Zhihong J. Wang. Treatment decisions and the use of mek inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer, Jun 2023. URL: https://doi.org/10.1186/s12885-023-10996-y, doi:10.1186/s12885-023-10996-y. This article has 97 citations and is from a peer-reviewed journal.
(souza2022clinicaltrialstargeting pages 6-7): Gabriel Roman Souza, Ahmed Abdalla, and Daruka Mahadevan. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-oncology Advances, Jan 2022. URL: https://doi.org/10.1093/noajnl/vdac005, doi:10.1093/noajnl/vdac005. This article has 18 citations and is from a peer-reviewed journal.
(imataka2025neurofibromatosistype1 pages 7-9): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.
(plante2024revisitingthenpcis pages 11-12): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.
(plante2024revisitingthenpcis pages 2-4): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.
(mclean2023singlecellrnasequencing pages 16-17): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.
(mclean2023singlecellrnasequencing pages 1-2): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

Deep Research

1. Disease Information

Overview

Key Identifiers

2. Etiology

Disease Causal Factors

Genetic Risk Factors

Environmental Risk Factors

3. Phenotypes

Clinical Manifestations of NF1 (with HPO term suggestions)

Quality of Life Impact

4. Genetic/Molecular Information

Causal Gene: NF1 (Neurofibromin 1)

Pathogenic Variants

Genotype-Phenotype Correlations

Malignant Transformation: Neurofibroma-to-MPNST Continuum

Epigenetic Information

5. Mechanism / Pathophysiology

Molecular Pathways

Cellular Processes

Tumor Microenvironment

Molecular Profiling

6. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Localization

7. Temporal Development

Onset

Progression

Prognosis

8. Inheritance and Population

Epidemiology

Inheritance

9. Diagnostics

Clinical Criteria

Genetic Testing

Imaging

Biomarkers for Malignant Transformation

10. Treatment

Current Treatment Landscape

Pharmacotherapy

Drug Targets (OpenTargets)

Surgical and Interventional

Experimental Therapies and Clinical Trials

11. Prevention

Primary Prevention

Secondary Prevention

Screening

12. Model Organisms

Mouse Models

Porcine Models

iPSC-Derived Models

Model Limitations

13. Summary

Artifacts